Publicação científica trimestral do CREMERJ - número 3 - 2022

103 Med. Ciên. e Arte , Rio de Janeiro, v.1, n.3, p.94-104, jul-set 2022 Diagnóstico e estratégia terapêutica na depressão resistente ao tratamento Walter dos Santos Gonçalves et al. 13. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. doi:10.1016/S0140-6736(17)32802-7 14. Tundo A, Filippis R de, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J Psychiatry. 2015;5(3):330. doi:10.5498/wjp.v5.i3.330 15. Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31(4):512-516. doi:10.1097/ JCP.0b013e3182228619 16. Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta- analysis of RCTs of a common therapeutic strategy: Review. Acta Psychiatr Scand. 2010;121(3):174-179. doi:10.1111/j.1600-0447.2009.01458.x 17. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016;61(9):540-560. doi:10.1177/0706743716659417 18. Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701. doi:10.1176/appi.ajp.2011.10111645 19. Si T, Wang P. When is antidepressant polypharmacy appropriate in the treatment of depression? Shanghai Arch Psychiatry. 2014;26(6):357-359. doi:10.11919/j.issn.1002-0829.214152 20. Nelson JC, Papakostas GI, J. Craig Nelson MD, George I. Papakostas MD. Atypical Antipsychotic Augmentation in Major Depressive Disorder: AMeta-Analysis of Placebo-Controlled Randomized Trials. Am J Psychiatry. 2009;166(September):980-991. doi:10.1176/appi.ajp.2009.09030312 21. Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord. 2014;168:269-275. doi:10.1016/j.jad.2014.05.053 22. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848. doi:10.1001/ archpsyc.1996.01830090090013 23. Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714-731. doi:10.1016/j.euroneuro.2017.04.003 24. Thomas SJ, Shin M, McInnis MG, Bostwick JR. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35(4):433-449. doi:10.1002/phar.1576 25. ANVISA. Agência Nacional de Vigilância Sanitária. https://consultas.anvisa.gov.br/#/pareceres/ q/?nomeProduto=SPRAVATO. Accessed April 14, 2022. 26. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined with a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616- 630. doi:10.1093/ijnp/pyz039 27. Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428-438. doi:10.1176/appi.ajp.2019.19020172 28. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry. 2018;75(2):139-148. doi:10.1001/jamapsychiatry.2017.3739